Identification of CK2 as the kinase that phosphorylates Pax3 at Ser209 in early myogenic differentiation

Biochemical and Biophysical Research Communications

Volumn 428, Issue 1, 2012, Pages 24-30

  Iyengar, Aditi S ^a   Loupe, Jacob M ^a   Miller, Patrick J ^a   Hollenbach, Andrew D ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CK2; Myogenesis; Pax3; Phosphorylation

Indexed keywords

CASEIN KINASE II; SERINE; TRANSCRIPTION FACTOR PAX3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; MOUSE; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CASEIN KINASE II; CELL DIFFERENTIATION; CELLS, CULTURED; MICE; MODELS, BIOLOGICAL; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MUTATION; MYOBLASTS, SKELETAL; PAIRED BOX TRANSCRIPTION FACTORS; PHOSPHORYLATION; SERINE;

EID: 84868346245     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.141     Document Type: Article

References (17)

1. Bober E., Franz T., Arnold H.H., Gruss P., Tremblay P. Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. Development 1994, 120:603-612.
2. Conway S.J., Henderson D.J., Kirby M.L., Anderson R.H., Copp A.J. Development of a lethal congenital heart defect in the splotch (Pax3) mutant mouse. Cardiovasc. Res. 1997, 36:163-173.
3. Ichi S., Boshnjaku V., Shen Y.W., Mania-Farnell B., Ahlgren S., Sapru S., Mansukhani N., McLone D.G., Tomita T., Mayanil C.S. Role of Pax3 acetylation in the regulation of Hes1 and Neurog2. Mol. Biol. Cell 2011, 22:503-512.
4. Boutet S.C., Disatnik M.H., Chan L.S., Iori K., Rando T.A. Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors. Cell 2007, 130:349-362.
5. Amstutz R., Wachtel M., Troxler H., Kleinert P., Ebauer M., Haneke T., Oehler-Janne C., Fabbro D., Niggli F.K., Schafer B.W. Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res. 2008, 68:3767-3776.
6. Miller P.J., Hollenbach A.D. The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. Biochim. Biophys. Acta 2007, 1770:1450-1458.
7. Miller P.J., Dietz K.N., Hollenbach A.D. Identification of serine 205 as a site of phosphorylation on Pax3 in proliferating but not differentiating primary myoblasts. Protein Sci. 2008, 17:1979-1986.
8. Dietz K.N., Miller P.J., Hollenbach A.D. Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation. Biochemistry 2009, 48:11786-11795.
9. Dietz K.N., Miller P.J., Iyengar A.S., Loupe J.M., Hollenbach A.D. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int. J. Biochem. Cell. Biol. 2011, 43:936-945.
10. Meggio F., Pinna L.A. One-thousand-and-one substrates of protein kinase CK2?. FASEB J. 2003, 17:349-368.
11. Allende J.E., Allende C.C. Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 1995, 9:313-323.
12. Meggio F., Shugar D., Pinna L.A. Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. Eur. J. Biochem. 1990, 187:89-94.
13. Rickert P., Corden J.L., Lees E. Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene 1999, 18:1093-1102.
14. Schang L.M. Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. 2002, 50:779-792.
15. Pei Y., Shuman S. Characterization of the Schizosaccharomyces pombe Cdk9/Pch1 protein kinase: Spt5 phosphorylation, autophosphorylation, and mutational analysis. J. Biol. Chem. 2003, 278:43346-43356.
16. Ahmad K.A., Wang G., Slaton J., Unger G., Ahmed K. Targeting CK2 for cancer therapy. Anticancer Drugs 2005, 16:1037-1043.
17. Wang G., Unger G., Ahmad K.A., Slaton J.W., Ahmed K. Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Mol. Cell. Biochem. 2005, 274:77-84.